CPRX
Catalyst Pharmaceuticals Inc
$
20.590
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
20.660
Open
20.440
VWAP
20.51
Vol
814.40K
Mkt Cap
2.52B
Low
20.390
Amount
16.71M
EV/EBITDA(TTM)
6.64
Total Shares
118.12M
EV
1.87B
EV/OCF(TTM)
6.79
P/S(TTM)
4.66
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
136.44M
-3.52%
0.350
-22.22%
136.80M
-3.54%
0.270
-38.64%
136.66M
+6.19%
0.330
-5.71%
Estimates Revision
The market is revising Upward the revenue expectations for Catalyst Pharmaceuticals, Inc. (CPRX) for FY2025, with the revenue forecasts being adjusted by 0.15% over the past three months. During the same period, the stock price has changed by -17.31%.
Revenue Estimates for FY2025
Revise Upward
+0.15%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-5.94%
In Past 3 Month
Stock Price
Go Down
-17.31%
In Past 3 Month
5 Analyst Rating
Wall Street analysts forecast CPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CPRX is 33.00 USD with a low forecast of 31.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 20.590
Low
31.00
Averages
33.00
High
35.00
Current: 20.590
Low
31.00
Averages
33.00
High
35.00
Baird
Joel Beatty
Buy
Maintains
$28 → $32
2025-03-03
Reason
Baird
Joel Beatty
Price Target
$28 → $32
2025-03-03
Maintains
Buy
Reason
Baird raised the firm's price target on Catalyst Pharmaceuticals to $32 from $28 and keeps an Outperform rating on the shares. The firm updated its model following its Q4 report as its Firdapse and Agamree are poised for a strong 2025.
HC Wainwright & Co.
Andrew Fein
Strong Buy
Reiterates
$35
2025-02-28
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$35
2025-02-28
Reiterates
Strong Buy
Reason
Stephens & Co.
Sudan Loganathan
Buy
Reiterates
$33
2025-02-27
Reason
Stephens & Co.
Sudan Loganathan
Price Target
$33
2025-02-27
Reiterates
Buy
Reason
Baird
Joel Beatty
Buy
Initiates
$28
2025-02-04
Reason
Baird
Joel Beatty
Price Target
$28
2025-02-04
Initiates
Buy
Reason
HC Wainwright & Co.
Andrew Fein
Strong Buy
Maintains
$30 → $35
2025-01-10
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$30 → $35
2025-01-10
Maintains
Strong Buy
Reason
B of A Securities
Jason Gerberry
Strong Buy
Reiterates
$30
2025-01-09
Reason
B of A Securities
Jason Gerberry
Price Target
$30
2025-01-09
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Catalyst Pharmaceuticals Inc (CPRX.O) is 15.48, compared to its 5-year average forward P/E of 13.83. For a more detailed relative valuation and DCF analysis to assess Catalyst Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
13.83
Current PE
15.48
Overvalued PE
18.26
Undervalued PE
9.40
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
2.97
Current EV/EBITDA
6.84
Overvalued EV/EBITDA
7.31
Undervalued EV/EBITDA
-1.37
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
3.99
Current PS
4.46
Overvalued PS
4.87
Undervalued PS
3.12
Financials
Annual
Quarterly
FY2025Q2
YoY :
+19.44%
146.56M
Total Revenue
FY2025Q2
YoY :
+22.22%
66.30M
Operating Profit
FY2025Q2
YoY :
+27.73%
52.11M
Net Income after Tax
FY2025Q2
YoY :
+24.24%
0.41
EPS - Diluted
FY2025Q2
YoY :
+11.15%
71.27M
Free Cash Flow
FY2025Q2
YoY :
-0.34%
79.56
Gross Profit Margin - %
FY2025Q2
YoY :
+8.78%
49.19
FCF Margin - %
FY2025Q2
YoY :
+6.95%
35.55
Net Margin - %
FY2025Q2
YoY :
+105.70%
28.49
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
3.3M
USD
3
3-6
Months
11.1M
USD
6
6-9
Months
7.0M
USD
4
0-12
Months
21.1M
USD
11
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
3.2M
Volume
2
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
2.1M
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
3.3M
USD
3
3-6
Months
11.1M
USD
6
6-9
Months
7.0M
USD
4
0-12
Months
21.1M
USD
11
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CPRX News & Events
Events Timeline
2025-08-25 (ET)
2025-08-25
08:14:43
Catalyst Pharmaceuticals reveals resolution of FIRDAPSE patent lawsuit
2025-08-06 (ET)
2025-08-06
17:54:41
Catalyst Pharmaceuticals reports Q2 EPS 68c, consensus 54c
2025-08-06
08:22:48
Catalyst announces NCCN Guidelines for SCLC include new additions
Sign Up For More Events
Sign Up For More Events
News
1.0
08-28NewsfilterCatalyst Pharmaceuticals to Attend Upcoming Investor Conferences
7.0
08-26Yahoo FinanceCatalyst Pharmaceuticals Reaches Settlement in FIRDAPSE® Patent Dispute with Lupin Pharmaceuticals
7.0
08-25SeekingAlphaCatalyst Pharmaceuticals reaches settlement in lawsuit with Lupin
Sign Up For More News
People Also Watch
CON
Concentra Group Holdings Parent Inc
23.800
USD
+0.25%
OII
Oceaneering International Inc
24.400
USD
-0.81%
MANU
Manchester United PLC
17.850
USD
+2.35%
TBBK
Bancorp Inc
76.240
USD
-2.11%
HUT
Hut 8 Corp
26.730
USD
+0.83%
AKR
Acadia Realty Trust
20.010
USD
-0.25%
MRUS
Merus NV
65.840
USD
-0.39%
YELP
Yelp Inc
31.620
USD
+1.05%
PRGS
Progress Software Corp
46.290
USD
-0.04%
BHC
Bausch Health Companies Inc
7.420
USD
+3.78%
FAQ
What is Catalyst Pharmaceuticals Inc (CPRX) stock price today?
The current price of CPRX is 20.59 USD — it has increased 1.03 % in the last trading day.
What is Catalyst Pharmaceuticals Inc (CPRX)'s business?
What is the price predicton of CPRX Stock?
What is Catalyst Pharmaceuticals Inc (CPRX)'s revenue for the last quarter?
What is Catalyst Pharmaceuticals Inc (CPRX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Catalyst Pharmaceuticals Inc (CPRX)'s fundamentals?
How many employees does Catalyst Pharmaceuticals Inc (CPRX). have?